Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    More Data is Needed to Prove the Safety of Metformin
    • Fang LIU, Nephrologist
    • Other Contributors:
      • Yanhuan FENG, Ping FU, Yujie LIAO

    Dear Editor, Metformin is the most widely used hypoglycemic agent in the world. But the application among the diabetic patients who have the chronic kidney disease(CKD) is still controversial. What gave us a pleasant surprise was the observational study written by Ekstrom et al found that there were no increased risks of acidosis/serious infection in patients with renal impairment according to the large numbers of patient...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Metformin is a safe medication in mild-to-moderate chronic kidney disease.
    • David Arroyo, Nephrologist
    • Other Contributors:
      • David Arroyo, Soledad Garcia de Vinuesa, and Jose Luno

    Dear Editor,

    Ekstrom and colleagues publish a very interesting observational study comparing the rates of various outcomes depending on the type of antidiabetic drug prescribed.(1) This large population-based study presents some limitations, such as baseline difference between groups, attributing outcomes to initial treatment regardless of changes over time, or grouping diverse outcomes such as acidosis and infec...

    Show More
    Conflict of Interest:
    None declared.